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The Venezuelan equine encephalitis virus (VEEV) serocomplex is
composed of arboviruses in the genus Alphavirus, family Togaviridae.
VEEV is an emerging zoonotic pathogen that has caused several serious
epizootics and epidemics in the last 20 years, largely in Central and
South America (Weaver et al., 2004). It is an NIAID Category B priority
pathogen, due principally to its growth to high titers in cell cultures,
stability in nature, high infectivity when aerosolized, high attack rate,
and its historical development as a bioweapon by both the US and the
former Soviet Union (Bronze et al., 2002; Hawley and Eitzen, 2001;
Weaver and Reisen, 2010). VEEV has also been responsible for a high
number of laboratory infections due to parenteral inoculation or
airborne exposure and was thus designated as a biocontainment level3 pathogen (The Subcommittee on Arbovirus Laboratory Safety of the
American Committee on Arthropod-borne Viruses, 1980).
In humans, VEEV can cause neurological disease, including convul-
sions, disorientation, drowsiness, andmental depression in up to 15% of
infections, with a higher rate in children (Johnson and Martin, 1974). A
mouse model for VEEV encephalitis has been widely used for studies of
pathogenesis and testing of vaccines and therapeutics (Jackson et al.,
1991; Kundin, 1966; Paessler et al., 2006). Infection ofmiceby either the
subcutaneous (SC) or intranasal (IN) routes leads to invasion of the
central nervous system(CNS), resulting in100%mortality (Jacksonet al.,
1991; Ryzhikov et al., 1995). In the immunocompetentmouse, both the
immune response to VEEV replication in the brain and direct
cytopathology in the CNS contribute to encephalitis, which is the
ultimate cause of death (Charles et al., 2001).
Currently there is no FDA-approved human vaccine for VEEV; TC-83,
an attenuated, live virus vaccine, is available only under Investigational
New Drug (IND) status to protect laboratory and military personnel. It
has been associated with poor immunogenicity and relatively high
reactogenicity (Pittman et al., 1996). Formalin-inactivated TC-83,
known as C-84, has been used as a vaccine but requires frequent
boosting and may not protect from aerosol infection (Jahrling and
Stephenson, 1984). Recently a live-attenuated vaccine, V3526, was
Table 1
Prophylactic efﬁcacy of human (h) MAb F5 nIgG for mice infected with virulent
Venezuelan equine encephalitis virus (VEEV) Trinidad Donkey (TrD) strain by
subcutaneous (SC) or aerosol routes.
hMAb
(μg)
HMAb prophylaxis for infected mice
SC VEEV infectiona Aerosol VEEV infectionb
%Survivorsc hIgGd mIgGe %Survivorsc hIgGd mIgGe
500 − − − 90 4299 b5
100 100 3715 b10
50 100 − − 100 479 b5
10 100 89 b10 − − −
1 80 b10 29 − − −
0.1 100 b10 912 − − −
0.01 0 − − − − −
PBS 0 − − 0 − −
−, Not done.
a 100scMD50, 20 PFU/0.1 ml.
b 100,000 PFU/5 ml.
c Ten mice per group.
d hIgG (F5 nIgG) geometric mean anti-VEEV ELISA titer of survivors' sera.
e Murine (m) IgG geometric mean anti-VEEV ELISA titer of survivors' sera.
Table 2
Virus replication in mouse tissues following prophylaxis with 50 μg human MAb F5
nIgG 24 h prior to aerosol infection with Venezuelan equine encephalitis virus (VEEV).
Mouse # 50 μg F5
nIgGa
Euthanasia and
tissue collection,
DPIb
VEEV titer
PFU/g brain
tissue
PFU/ml
serum
1 + 1 b100 b100
2 + 1 b100 b100
3 + 1 b100 2200
4 + 3 b100 b100
5 + 3 b100 b100
6 + 3 b100 b100
7 + 5 700 b100
8 + 5 b100 b100
9 + 5 b100 b100
10 − 6.5 5.5×109 b100
11 − 6.5 2.1×109 −
12 − 6.5 9.8×109 b100
−, Not done.
a Intraperitoneal administration 24 h prior to infection.
b DPI, days post-infection.
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cDNA clone. Although it was effective in animal studies, adverse events
in phase 1 clinical trials resulted in itswithdrawal (Fineet al., 2008; Pratt
et al., 2003; Reed et al., 2005). In the absence of an approved vaccine or
speciﬁc treatment for VEEV infections, there is a need for development
of antiviral therapeutics that could penetrate the blood–brain barrier
and limit viral replication in the CNS.
Using Sindbis virus (SINV) in SCID mice as a model of alphaviral
encephalitis, Grifﬁn and colleagues showed that adoptive transfer of
hyperimmune mouse serum or monoclonal antibodies (MAb) to
epitopes on the E2 envelope glycoprotein resulted in clearance of
infectious virus and viral RNA from the CNS (Levine et al., 1991).
Recovery was dependent on immune-mediated, non-cytolytic control
and clearance of infectious virus from neurons, which are long-lived,
terminally differentiated cells (Grifﬁn, 2010); viral clearance was not
accomplished by transfer of puriﬁed SINV-sensitized T cells or
dependent on host cytolytic factors. Phillpotts and colleagues showed
that intraperitoneal (IP) administration of murine anti-VEEV E2
glycoprotein MAbs either 24 h before or immediately after aerosol
challenge with virulent virus could protect mice from lethal disease
(Phillpotts, 2006; Phillpotts et al., 2002). Prophylactic MAbs 1A3A-9
or 1A4A-1 protected 90–100% of virus-challenged mice; post-
exposure treatment with MAb 1A3A-9 protected 47% of mice. VEEV-
infected mice treated therapeutically 24 h post-infection (PI) had
signiﬁcant reductions in virus titers in peripheral organs by 5 days PI
but titers were not reduced in brains (Phillpotts et al., 2002). Paessler
et al. (2006) found that immunization ofmicewith avirulent, chimeric
SIN/VEE viruses resulted in protection from lethal encephalitis
following SC, IN or intracranial (IC) challenge with virulent VEEV.
Although vaccination of mice elicited neutralizing antibodies, high
levels of infectious challenge virus were found in the brains of mice
3 days PI (regardless of the challenge route), but were undetectable
by 28 days PI.
In past studies we used murine (m) MAbs to analyze the antigenic
structure of the VEEV E1 and E2 glycoproteins and determined that
epitopes on the E2 protein located between amino acids (AA) 182–
207 constituted a major neutralization domain (Roehrig et al., 1982;
Roehrig and Mathews, 1985). MAbs speciﬁc for this domain have
potent protective activity in a murine model when administered 24 h
before or 24 h after peripheral or aerosol challengewith virulent VEEV
(Mathews and Roehrig, 1982; Mathews et al., 1985; Phillpotts, 2006;
Phillpotts et al., 2002). However, neutralizing anti-VEEV mMAbs are
limited in their clinical application due to the human anti-mouse
antibody response. Recently we reported the isolation of a human (h)
MAb, F5 nIgG, which is speciﬁc for a newly recognized neutralization
epitope (AA 115–119) on the VEEV E2 protein (Hunt et al., 2010). In
this report we document the efﬁcacy of this hMAb in protecting mice
prior to or following either peripheral or airborne VEEV challenge.
Results
Prophylactic protection from virulent VEEV challenge by passive transfer
of hMAb F5 nIgG
To determine prophylactic efﬁcacy of neutralizing hMAb F5 nIgG,
we challenged mice by either SC or aerosol exposure to virulent VEEV
24 h after passive transfer of hMAb F5. Six groups of 10 mice each
were inoculated IP with varying doses (0.01–100 μg) of puriﬁed hMAb
F5 and challenged 24 h later by SC injection of 100sc 50% morbidity
doses (MD50) (20 PFU/0.1 ml) of virulent VEEV Trinidad donkey (TrD)
strain (Table 1). The survival rate of the groups given 0.1–100 μg
hMAb was 80–100% (Pb0.001, two-tailed Fisher's exact test). None of
the mice in either the control (PBS-treated) group or the group
treatedwith 0.01 μgMAb survived virus challenge. Both 500 and 50 μg
passively transferred hMAb F5 protected 90–100% of mice challenged
24 h later with 100aeroMD50 aerosolized VEEV (Pb0.0002; Table 1).High titers of passively transferred hMAb persisted 14 days after
challenge in sera of survivors inoculated with 500 μg of antibody prior
to aerosol infection or 100 μg of antibody prior to SC challenge. A
murine antibody response to VEEV was undetectable in animals given
≥10 μg hMAb, indicating that sterilizing immunity had been
established in these animals. Mice inoculated prophylactically with
1 or 0.1 μg hMAb mounted an immune response following SC
challenge, resulting in the production of murine anti-viral antibody
that might have contributed to protection from virus challenge
(Table 1).
To assess the ability of hMAb F5 to prevent virus replication,
groups of 3 mice were inoculated IP with 50 μg hMAb F5 24 h prior to
aerosolized VEEV challenge and euthanized on days 1, 3, and 5 PI.
Brain tissue and serum samples were obtained from each treated
animal as well as from 3 untreated controls for titration of infectious
VEEV by plaque assay (Table 2). The limits of virus detection were
100 PFU/g for brain tissue and 100 PFU/ml for sera. Little to no virus
was detected in tissues of hMAb F5-treated mice compared to the
untreated controls, which had brain titers of 109.8 PFU/g. As expected,
serum samples from untreated mice contained no detectable
infectious virus at 6.5 days PI; however, a geometric mean titer
(GMT) of 105.7 PFU/ml serum was determined for samples from 11
Table 3
Therapeutic efﬁcacy of human (h) MAb F5 nIgG inoculated intraperitoneally (IP) 24 h
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construct Fig. 1).post-infection for mice infected with virulent Venezuelan equine encephalitis virus
(VEEV) Trinidad Donkey (TrD) strain by subcutaneous (SC) or aerosol routes.
MAb therapy for infected mice
SC VEEV infectiona Aerosol VEEV infectionb
hMAb (μg) %Survivorsc hIgGd mIgGe %Survivorsc hIgGd mIgGe
500 90 b10 6813 100 107 ≥74
50 30 b10 12,589 80 b10 79
10 0 − − − − −
PBS 0 − − 0 − −
−, Not done.
a 100scMD50, 20 PFU/0.1 ml.
b 100,000 PFU/5 ml.
c Ten mice per group.
d hIgG (F5 nIgG) geometric mean anti-VEEV ELISA titer of survivors' sera.
e Murine (m) IgG geometric mean anti-VEEV ELISA titer of survivors' sera.
Table 4
Persistence of infectious virus and viral RNA in mouse brains following infection with
aerosolized Venezuelan equine encephalitis virus (VEEV) and treatment with 50 μg
human (h) MAb F5 nIgG 24 h post-infection (PI).Therapeutic efﬁcacy of passively transferred hMAb F5 nIgG following
virulent VEEV challenge
Based on preliminary experiments, doses of 500 or 50 μg of
passively transferred hMAb F5 were chosen to determine therapeutic
efﬁcacy following SC or aerosol challenge with virulent VEEV. Groups
of 10 mice were infected by SC inoculation of 100scMD50 or aerosol
exposure to 65aeroMD50 VEEV TrD, 24 h prior to IP hMAb transfer.
Treatment with a 500 μg dose of hMAb F5 within 24 h of infection
resulted in 90% to 100% survival of mice infected by either route
(Table 3). Signiﬁcant recovery (Pb0.0002) after SC infection was
provided by a dose of 500 μg but not 50 μg of hMAb F5. Surviving mice
that received either treatment dose mounted an anti-viral immune
response that generated high murine antibody titers in sera collected
on day 14 PI. However, hMAb was not detectable in survivor sera,
although it had been observed when 500 μg or 100 μg hMAb was
administered prophylactically (Table 1).
Surprisingly, recovery of mice infected with VEEV by the aerosol
route was achieved more efﬁciently than those infected SC; both 500
and 50 μg doses of hMAb protected mice in this study (Table 3;
Pb0.001). Sera from aerosol-infected groups of surviving mice also
had much lower mIgG ELISA titers than mice infected by the SC route.
To determine the ability of a 50 μg therapeutic dose of hMAb F5 to
control VEEV replication following aerosol exposure, groups of hMAb
F5-treated and untreated mice were euthanized on days 1 to 6 PI and
serum, brain, lung, spleen, heart, liver, and kidney samples were
assayed for infectious virus (Fig. 1; Table S1). Untreated mice
developed maximum virus GMTs of 106.0 to 109.4 PFU/g tissue as
early as 1 day PI for lung tissue (106.5 PFU/g) and by 4 to 5 days PI for
other tissues. Virus titers in all tissue samples except brain from hMAb
F5-treated mice ranged from below the minimum detection limit
(b102 PFU/g) to 103 PFU/g. Unexpectedly, hMAb-treated mice that
exhibited no clinical signs of disease had virus titers in brain samples
equivalent to those from untreated animals.
In our initial experiment, hMAb-treated mice were observed for
6 days following infection—the average survival time of naïve mice
infected with VEEV TrD. Following prophylactic administration, only
two mice had low levels of detectable infectious virus in brain or
serum at any time PI (Table 2). In contrast, untreated mice had in0
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Fig. 1. Titer of Venezuelan equine encephalitis virus (VEEV) in various tissues for 6 or
7 days following aerosol infection in both untreated mice and mice treated
intraperitoneally with 50 μg of human (h) MAb F5 nIgG 24 h post-infection. Geometric
mean titers (GMT) of VEEV per gram tissue from untreated mice are shown with solid
lines and from hMAb-treated mice with dotted lines. For untreated mice, GMTs were
determined from n=3 mice for days 1, 2, 3, 5, and 6 and n=3 for day 4; for hMAb-
treated mice, GMTs were determined from n=3mice for days 2 and 3, n=2 for days 4
and 5, and n=1 for day 6. Tissues: serum (♦, red), brain (●, gray), lung (▲, pink),
spleen (■, green), heart (×, blue), liver (−, brown), and kidney (+, cyan).excess of 109 PFU/g brain tissue when they were euthanized at day 6.5
PI. VEEV infection of the brain following aerosolized delivery was thus
prevented by prophylactic administration of 50 μg hMAb F5. Despite
survival of mice treated therapeutically 24 h PI, virus titers in brains of
treated mice were equivalent to those of untreated mice sampled on
days 3 to 6 after infection (Fig. 1). We therefore conducted an
additional trial to determine how long infectious virus and viral RNA
persisted in brains after VEEV aerosol challenge followed 24 h later by
hMAb F5 treatment (Table 4). In this experimental protocol the
untreated mice became severely ill on days 6 or 7 PI and were
euthanized. Three hMAb F5-treated mice were euthanized on each of
days 7, 14, and 28 PI, and brain tissues were assayed for infectious
virus by plaque titration and for viral RNA by qRT-PCR. The untreated
mice had a GMT of 109.6 PFU/g brain tissue following euthanasia on
days 6 or 7 PI. The virus titer on day 7 PI in brain tissue from mice
treated at 24 h PI with 50 μg hMAb varied from undetectable
to109.4 PFU/g. By 14 days PI, no virus could be demonstrated in the
F5-treated mouse brains, although 2 of 3 brains contained low levels
of viral RNA as determined by qRT-PCR. By 28 days PI, neitherMouse brain no. 50 μg F5
nIgGa
Euthanasia
and tissue
collection
DPIb
VEEV PFU/g
tissue
qRT-PCR for viral RNA
Mean CTc CT Std. Dev.
MBC-1d − 6 4.3×109 16.06 0.32
MBC-2 − 6 3.6×108 18.04 0.25
MBC-3 − 7 6.8×109 17.27 0.50
MB-1 + 7 2.4×106 19.91 0.23
MB-2 + 7 b100 31.73 0.16
MB-3 + 7 800 25.12 0.20
MB-4 + 14 b100 32.37 0.26
MB-5 + 14 b100 31.33 0.14
MB-6 + 14 b100 NAe −
MB-7 + 28 b100 NA −
MB-8 + 28 b100 NA −
MB-9 + 28 b100 NA −
qRT-PCR controls
VEEV RNA 1:5 − − − 17.39 0.09
VEEV RNA 1:50 − − − 21.09 0.34
Water only − − − NA −
No template − − − NA −
−, Not done.
a 24 h PI, intraperitoneally.
b DPI, days post-infection.
c CT, threshold cycle; values ≤38.5 interpreted as positive.
d C-1, -2, -3, virus-infected, untreated mice.
e NA, no ampliﬁcation.
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hMAb-treated mouse brain samples (Table 4).
Detection of VEEV antigen by IHC in brain tissue from untreated and
hMAb F5 nIgG-treated mice
To determine if the same brain regions and cell types were infected
in hMAb-treated and untreated mice, tissue samples were harvested
at 5 days PI from several areas of the CNS including olfactory bulb,
brainstem, cerebrum and cerebellum, ﬁxed, embedded in parafﬁn,
and sectioned for IHC detection of VEEV antigen. Similar intensities
and patterns of virus antigen were detected in neurons from all areas
of the CNS examined in both untreated and hMAb-treated mice
(Fig. 2). These ﬁndings were in agreement with the results from
plaque assays demonstrating the presence of high viral titers in the
brains of both hMAb F5-treated and untreated VEEV-infected mice
(Fig. 1).
Discussion
We previously described the antigenic structure of both the VEEV
E1 and E2 glycoproteins using mMAbs, as well as identifying viral
epitopes most important in themurine protective response (Mathews
and Roehrig, 1982; Mathews et al., 1985; Roehrig andMathews, 1985;
Roehrig et al., 1982). More recently, we mapped the VEEV epitopes
recognized by hMAbs (Hunt et al., 2010) and selected hMAb F5 nIgG,
which has signiﬁcant neutralizing ability and is speciﬁc for a unique
E2 protein epitope, AA 115–119, for evaluation of its potential to
provide either pre- or post-exposure protection from both SC and
aerosol challenge with virulent VEEV TrD in a murine model.
The association of in vitroneutralizing activitywith in vivoprotection
using anti-VEEV mMAbs or humanized mMAbs is well-documented
(Hunt et al., 2006; Mathews and Roehrig, 1982; Phillpotts, 2006;
Phillpotts et al., 2002). F5 nIgG had a VEEV TC-83 70% plaque-reduction
neutralization endpoint of 12.5 ng/ml, which compares favorably to
average endpoints of 29 and 100 ng/ml for humanized Hy4 IgG and
mMAb 3B4C-4, respectively (Hunt et al., 2006, 2010). Prophylactic
administration of 100 μg or 500 μg of Hy4 resulted in signiﬁcant
protection from IP or IN VEEV challenge, respectively (Hunt et al.,
2006); thus, we expected F5 nIgG to provide prophylactic protection
from SC or aerosol challenge with VEEV TrD in a similar manner. We
found that prophylactic administration of 50 μg of F5 nIgG resulted in
similar levels of protection from aerosol challenge as 500 μg of Hy4 IgG
provided against IN VEEV challenge (Hunt et al., 2006; Table 1). As little
as 100 ngof eitherHy4or F5protected90–100%ofmice from lethal IP or
SC challenge, and survivor sera contained signiﬁcant murine anti-VEEV
titers but little to no residual human antibody (Hunt et al., 2006;Fig. 2. Immunohistochemistry of Venezuelan equine encephalitis virus-infected mouse bra
treated with hMAb F5 nIgG 24 h PI (B).Table 1). Administration of 50 μg of prophylactic F5 nIgG resulted in
complete protection and almost complete sterilizing immunity in mice
that survived subsequent challenge with aerosolized VEEV, as evi-
denced by both the lack of a murine anti-VEEV humoral response in
challenge survivors and the inability to detect infectious virus in most
serum and brain samples collected on days 1 to 5 post-challenge
(Tables 1, 2). These data support results of previous studies with anti-
VEEV neutralizing MAbs 1A4A-1, 1A3A-9, 1A3B-7 and 3B2A-9, which
documented the protective capacity of mMAbs from SC and aerosol
VEEV challenge (Phillpotts, 2006; Phillpotts et al., 2002).
We found that a dose of 500 μg F5 nIgG was effective in protecting
mice 24 h after either SC or aerosol infection with VEEV TrD (Table 3).
In our study, murine anti-VEEV titers in mice treated after SC virus
infection were signiﬁcantly higher than in mice infected by the
aerosol route; no hIgG could be detected after 14 days in mice that
survived SC challenge (Table 3). Phillpotts et al. (2002) reported that
100 μg mMAb 1A3A-9 provided signiﬁcant post-exposure protection
to mice when administered 2 or 24 h, but not 72 h, following aerosol
VEEV infection. They also showed that 24 h-post-exposure treatment
of VEEV-infected mice with mMAb led to signiﬁcant reductions in
virus titers in peripheral organs for 5 days PI, but not in brains of about
half of treated mice. This ﬁnding led the investigators to suggest that
although MAb given prophylactically could prevent virus replication
in the brain, therapeutic activity depended on both rapid clearance
from the periphery and prevention of virus infection of the brain and
that treatment would have little effect once a CNS infection was
established. We followed VEEV titers in tissue and serum samples
from F5 nIgG therapeutically treated and untreated mice for 6 days
after aerosol infection and also found that infectious virus replication
was controlled in the periphery, but not in the brain (Fig. 1).
Demonstration of similar intensity and cell speciﬁcity of virus antigen
expression in the brains of hMAb-treated and untreated mice was
conﬁrmed by detection of virus antigen in neurons by IHC (Fig. 2).
Subsequently, we followed hMAb-treated mice for 28 days PI and
found that infectious virus as well as viral RNA was cleared from
brains by 14–28 days PI (Table 4). Despite initial high titers of virus in
brains, none of the mice euthanized on days 7, 14, or 28 following
infection showed any clinical signs of disease.
We have not yet investigated a possible increase in pharmacologic
potency by administering a mixture of MAbs Hy4 IgG and F5 nIgG.
Mixing of mMAbs 1A4A-1 and 1A3A-9 demonstrated no enhanced
efﬁcacy when used for treatment (Phillpotts et al., 2002). Because F5
and Hy4 bind to different regions on the E2 protein, it is feasible that
this mixture might show enhanced efﬁcacy. Additionally, cocktails of
therapeutically relevant antibodies could reduce the probability of
selecting resistant strains or neutralization-escape variants in vivo
(Sanna et al., 2000).ins harvested at 5 days post-infection (PI) from an untreated mouse (A) or a mouse
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complex association of the immune response in CNS disease
pathogenesis and recovery is well established (Grifﬁn, 2010). Unlike
SINV, VEEV is directly cytopathic for cells of the CNS in the absence of
an immune response (Charles et al., 2001). Although T cells and their
related cytokines, especially IFN-γ, have a prominent role in clearing
virus from the CNS, mice deﬁcient in mature B cells are not able to
clear virus from the brain or prevent persistent virus replication
(Grifﬁn, 2010). For protection by passive antibody transfer, viral
clearance is dependent on the amount and speciﬁcity of antibody
transferred; antibody to the E2 protein is most effective (Johnston and
Peters, 1996). In the current study the amount of IP-administered
anti-E2 F5 nIgG required for effective prophylaxis was as little as
100 ng for subsequent SC VEEV challenge and 50 μg for aerosol
challenge (Table 1). The effective dose of post-exposure F5 nIgG,
delivered 24 h PI, was 500 μg for SC VEEV infection or 50 μg for aerosol
infection (Table 3). Local production of antibody in the CNS or nasal
mucosa may also play a role in protection and continued suppression
of viral replication due to persistant viral RNA (Charles et al., 1997;
Elvin et al., 2002; Grifﬁn, 2010). Although SINV RNA was detected by
RT-PCR for 12 months after infection in mice effectively treated with
passive antibody (Levine and Grifﬁn, 1992; Levine et al., 1991), we
found no detectable viral RNA 14–28 days PI in brain tissue frommice
infected by aerosolized VEEV and treated 24 h PI with 50 μg F5 nIgG.
The mechanism of antibody suppression of intracellular virus
replication is not completely understood but appears to require
bivalent antibody and is independent of IgG isotype (Ubol et al.,
1995).
Human exposure to VEEV in nature is usually mosquito-transmitted
and related to the occurrence of epizootic disease in equines and can
probably be best controlled by routine vaccination of equine popula-
tions (Johnson and Martin, 1974). In addition, humans (laboratorians,
veterinarians or ﬁeld workers) can be occupationally exposed to VEEV
via injection or aerosol routes (Slepushkin, 1959; Zarate and Scherer,
1968) or through an act of bioterrorism (intentional release). Because
no FDA-licensed, human vaccine or speciﬁc antiviral drugs are currently
available, an antiviral, protective hMAb for passive immunization has a
number of advantages: (1) provides a state of immediate immunity and
can be used prophylactically, (2) is highly speciﬁc and (3) has minimal
toxicity or reactogenicity for the human host. Technological develop-
ments in antibody engineering and recombinant DNA technology, as
well as antibiotic resistance, have created more interest in passive
antibody immunization for prevention and treatment of infectious
diseases (Casadevall, 2002; Casadevall et al., 2004; Krause et al., 1997;
Weltzin andMonath, 1999; Zeitlin et al., 1999). Several antibody-based
therapies are being developed for viral encephalitides. A phase I clinical
study of the safety, pharmacokinetics, and immunogenicity of a
neutralizing, recombinant humanized mMAb (MGAWN1) targeting
the E glycoprotein of the encephalitogenic ﬂavivirusWest Nile virus has
recently been reported (Beigel et al., 2010). A hMAb cocktail that
neutralizes rabies virus has been evaluated in phase I studies as an
alternative strategy to human and equine rabies immunoglobulin for
post-exposure prophylaxis in humans (Bakker et al., 2008).
Although themousemodel for VEEV disease is considered to closely
reﬂect the disease process in humans, studies in different immuno-
competent inbred mouse strains (Balb/c, C3H/HeN, A/J) have revealed
some variability in response to vaccines or passive antibody immuni-
zation (Elvin et al., 2002; Hart et al., 2000; Kinney et al., 1988; Phillpotts
et al., 2002). We have used outbred mice (ICR or SwissWebster) in our
evaluations of the protective capacity of human or humanized anti-
VEEV E2MAbs in an effort to assess an overall species response (Hunt et
al., 2006). Our results suggest that hMAb F5 nIgG is a valuable antiviral,
capable of providing both pre- and post-exposure protection from
peripheral and aerosol VEEV challenge, if used at appropriate doses. It is
also effective in reducing or eliminating persistent viral RNA replication.
Since passively administered humanized antibody titer inmouse serumwas fairly stable over a 2-week period, prophylactic protection for a
similar period is theoretically possible (Hunt et al., 2006); however,
therapeutic doses must be given within 24 h of infection for signiﬁcant
survival rates since the average survival time of VEEV-infected mice is
only about 6 days. The VEEV-infected, passively immunized mouse
model will also provide a good platform for future studies of the
contributions of other components of the immune response to disease
or survival of animals. In addition, further evaluation of the potential of
anti-VEEV passive human antibody is needed in nonhuman primates.
Materials and methods
Viruses and antibodies
VEEVs used in this study were subtype 1AB, strains TC-83 and TrD,
obtained from the Centers for Disease Control and Prevention (CDC),
Division of Vector-BorneDiseases (DVBD), Fort Collins, CO. Viruseswere
grown in Vero or BHK-21 cells and puriﬁed by equilibrium density
gradient centrifugation (Obijeski et al, 1976). Outbred ICR mice were
exposed to serial 10-fold dilutions of VEEV TrD to determine the MD50
for both SC and aerosol routes of infection. MD50were calculated by the
method of Reed andMuench (1938). MAbs Hy4 IgG (clone 26 C) and F5
nIgG (clone 1E9) have been previously described (Hunt et al., 2006,
2010). Both MAbs were expressed from stable 293-EBNA cell lines and
puriﬁed on a protein A column using FPLC.
Enzyme immunoassays
Indirect ELISAs were performed essentially as previously described
(Hunt et al., 2006; Roehrig et al., 1980), using native TC-83 virus as
antigen (1 μg/well). Speciﬁc binding of passively administered hMAbs
and murine antiviral antibodies in murine sera were detected by goat
anti-human Fc-speciﬁc- or goat anti-mouse IgG-alkaline phosphatase
(AP) conjugates, respectively. An absorbance ratio (A405 sample/A405
negative control) N2 was considered to be positive.
Passive antibody transfer and virus challenge in mice
Outbred adult ICR mice, 6–8 weeks old, were used for all passive
antibody protection studies. The use of animals for research purposes
complied with relevant federal guidelines and speciﬁc protocols were
approved by the Colorado State University Institutional Animal Care
and Use Committee.
For studies usingprophylactic antibody treatment, groups of 10mice
were inoculated IP with 100 μl containing speciﬁed amounts of puriﬁed
MAb F5 nIgG approximately 24 h prior to virus challenge. For
therapeutic treatment, mice were inoculated IP with MAb 24 h after
virus infection. Mice were challenged either SC with 100scMD50
(20 PFU/0.1 ml) of VEEV TrD or by aerosol route with a dose of
approximately 65aeroMD50 (100,000 PFU/5 ml). Aerosols containing
VEEV were produced using an Inhalation Exposure System (GlasCol,
Inc., Terre Haute, IN) in a BSL-3 suite. A wire-mesh basket with 5
compartments held the mice during the aerosolization process. Both
MAb-treated and control groups of mice, located in separate compart-
ments, were exposed to virus at the same time. Five milliliters of virus
stock solution diluted in PBS (20,000 PFU/ml) were injected into the
nebulizer and timers were set for a 20-min nebulizing cycle, a 20-min
cloud-decay time, and a 15-min decontamination period. Although
virus concentrationswithin the aerosol streamwere notmonitored, the
MD50 values were determined by repeated trials in which serial
dilutions of stock virus were placed in the nebulizer, and mouse
morbidity/mortality recorded. Additionally, untreated, VEEV-infected
animals were included in every experimental trial using hMAb
treatment of infected mice. Over years of use, we have found this
system to deliver consistent concentrations of organisms to mouse
lungs. All mice were monitored for signs of illness for 2 weeks and
151A.R. Hunt et al. / Virology 414 (2011) 146–152survivors were bled 14 days post-challenge. Although some animals
died from VEEV infection, death was not a required endpoint, and
animals were euthanized when they exhibited severe illness or
paralysis.
Replication and clearance of virus from the brains of untreated and MAb
F5-treated mice
Studies to monitor infectious virus and viral RNA were conducted
using smaller groups of mice (n=3) infected with aerosolized VEEV.
Mice were either prophylactically or therapeutically treated with
hMAb F5 or untreated, and serum and tissue samples were collected
for virus titration on days 1 through 6 PI. Tissue samples were frozen
at−80 °C until they were processed by homogenizing in BA1 diluent
[1× M199 with Hank's balanced salt solution, 0.05 M Tris buffer (pH
7.6), 1% bovine serum albumin, 0.35 g/l sodium bicarbonate, 100 mg/l
streptomycin, 1 mg/ml Fungizone] as 10% suspensions using a mixer
mill. The suspensions were clariﬁed by centrifugation and superna-
tants and sera were assayed by plaque titration on Vero cell
monolayers.
A longer term study for 28 days evaluated the presence of
infectious virus and viral RNA in the brains of mice exposed to
aerosolized VEEV and treated with MAb F5 24 h post-exposure. Brain
tissue samples were collected from 3mice on days 6/7, 14, and 28 and
were processed and assayed for virus as described above. In addition,
0.4 ml of each 10% brain homogenate supernatant was added to 2 ml
of Trizol Reagent (Invitrogen, Carlsbad, CA) and frozen at −80 °C for
subsequent RNA extraction.
RNA extraction and quantitative (q) RT-PCR
Viral RNA was extracted from mouse brain homogenate superna-
tants (0.4 ml), processed as described above, using a PureLink RNA
Mini Kit (Invitrogen) according to the manufacturer's instructions.
RNAwas eluted in 50 or 100 μl RNase-free water, quantitated using an
ND1000 NanoDrop spectrophotometer (ThermoScientiﬁc, West Palm
Beach, FL), and stored at −80 °C until used. Quantitative RT-PCR
assays were performed with 50 ng of extracted RNA, 50 pmol of each
VEEV TC-83 primer, and 10 pmol of a dual-labeled VEEV TC-83 probe
containing a FAM ﬂuorescent reporter at the 5′ end and TAMRA
quencher molecule at the 3′ end, in a total volume of 50 μl using the
Quantitect Probe RT-PCR Kit (Qiagen, Valencia, CA) according to the
manufacturer's instructions. The VEEV TC-83 primers and probe were
kindly provided by Dr. R. S. Lanciotti of DVBD, CDC, Ft. Collins, CO.
Ampliﬁcation and ﬂuorescence detection were performed on the
iCycler (Bio-Rad Laboratories, Hercules, CA). As recommended by the
manufacturer, 45 ampliﬁcation cycles were performed. Results were
determined by the ampliﬁcation cycle at which ﬂuorescence
increased above the threshold value (set at 104 relative ﬂuorescence
units) by use of the PCR baseline-subtracted curve ﬁt analysis mode.
Samples with a threshold cycle (CT) value of ≤38.5 were considered
positive.
Immunohistochemistry (IHC)
Tissues from mice infected with VEEV TrD were ﬁxed in buffered
formalin, embedded in parafﬁn and sectioned. For IHC the sections
were deparafﬁnized, treated with proteinase K for 10 min and
blocked by sequential treatment with hydrogen peroxide (10 min),
glycine buffer (15 min), and blocking solution (overnight). The
sections were then treated overnight with mouse anti-VEEV (TC-
83) ascitic ﬂuid (CDC VS0119) diluted 1:200 in blocking solution,
washed, and incubated with horseradish peroxidase-labeled anti-
mouse IgG. The sections were washed again, exposed to the substrate
diaminobenzidene-tetrahydrochloride and counterstained with Lillie's
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